BC Week In Review | Feb 15, 2019
Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

Samsung Bioepis Co. Ltd. (Incheon, South Korea) partnered to develop four of its biosimilars with AffaMed Therapeutics (Shanghai, China). The partners will initially collaborate on clinical development, regulatory registration and commercialization Ontruzant, SB11, SB12 and...
BC Extra | Sep 13, 2014
Financial News

Affimed raises $56M in IPO

Affimed Therapeutics B.V. (NASDAQ:AFMD) was down $1.30 to $5.70 on its first day of trading Friday after raising $56 million through the sale of 8 million shares at $7 in an IPO. The IPO price...
BC Week In Review | Mar 17, 2014
Company News

Formycon, Santo Holding GmbH deal

In December, Formycon (formerly Nanohale AG ) granted investment holding company Santo exclusive, worldwide rights to develop and commercialize an undisclosed biosimilar product. This is the biosimilar company's first licensing deal. Formycon will conduct all further...
BC Week In Review | Jan 16, 2012
Company News

Nanohale, Scil Technology deal

Nanohale acquired Scil Technology for an undisclosed sum. Scil will become part of Nanohale's newly-formed Formycon GmbH subsidiary. Nanohale said that Scil Technology's protein drug development, formulation and analytics programs complement Nanohale's existing protein formulation....
Items per page:
1 - 4 of 4